Results 41 to 50 of about 1,100,787 (194)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review

Current Therapeutic Research, 2022
: Background: Coronavirus disease 2019 (COVID-19), an acute, sometimes severe respiratory illness caused by a novel coronavirus has led to a vast pandemic with an astonishing spread rate.
Mitra Rezaei, MD, Saghar Barati, Pharm-D, PhD, Abdolreza Babamahmoodi, MD, Farzaneh Dastan, Pharm-D, PhD, Majid Marjani, MD   +4 more
doaj   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming   +15 more
wiley   +1 more source

How I Manage Chronic Lymphocytic Leukemia

Hematology Reports, 2023
Chronic lymphocytic leukemia (CLL), is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. CLL is the most prevalent leukemia in Western countries.
Patrice Nasnas, Claudio Cerchione, Gerardo Musuraca, Giovanni Martinelli, Alessandra Ferrajoli   +4 more
doaj   +1 more source

Treatment‐driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B‐cell therapy in Sjögren's disease

Arthritis &Rheumatology, Accepted Article.
Objective To characterise whole‐blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or BlyS/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to non‐response. Methods Whole‐blood RNA sequencing was performed at baseline and week‐24 in participants (n=43) from a
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Jørgensen, Heather G., Holyoake, T.L., Holyoake, T., Abed El Baky, Mohamed, Bartholomew, C., Melo, Junia V., Roy, P., Melo, J.V., Abed El Baky, M., Roy, S., Jørgensen, H., Jorgensen, H.G., Strathdee, G., Strathdee, Gordon, Melo, J., Roy, Swagata, Holyoake, Tessa L., Roy, Poornima, Bartholomew, Christopher   +18 more
core   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?

ImmunoTargets and Therapy, 2020
Ana Lorenzo-Vizcaya,1 Serena Fasano,2 David A Isenberg3 1Department of Internal Medicine, Hospital Universitario De Ourense, Ourense, Spain; 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Campania L.
Lorenzo-Vizcaya A, Fasano S, Isenberg DA
doaj  

Second primary cancers in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia—cumulative burden without generalized excess cancer risk

British Journal of Haematology, EarlyView.
Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard, Lars Moeller Pedersen, Lise Mette Rahbek Gjerdrum   +2 more
wiley   +1 more source

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report

Leukemia Research Reports
Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing survival benefits over traditional chemoimmunotherapy.
Tung-Lin Chiang, John Frater, Amanda Cashen   +2 more
doaj   +1 more source

A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome

Cells, 2023
In chronic lymphocytic leukemia (CLL), an elevated glycosyltransferase UGT2B17 expression (UGT2B17HI) identifies a subgroup of patients with shorter survival and poor drug response. We uncovered a mechanism, possibly independent of its enzymatic function,
Antoine Wagner, Michèle Rouleau, Lyne Villeneuve, Trang Le, Cheryl Peltier, Éric P. Allain, Caroline Beaudoin, Sophie Tremblay, Fréderic Courtier, Flora Nguyen Van Long, Isabelle Laverdière, Éric Lévesque, Versha Banerji, Katrina Vanura, Chantal Guillemette   +14 more
doaj   +1 more source